193 related articles for article (PubMed ID: 2596125)
1. Urinary gonadotropin fragment (UGF) measurements in the diagnosis and management of ovarian cancer.
Cole LA; Nam JH
Yale J Biol Med; 1989; 62(4):367-78. PubMed ID: 2596125
[TBL] [Abstract][Full Text] [Related]
2. Urinary gonadotropin fragment, a new tumor marker. II. Differentiating a benign from a malignant pelvic mass.
Cole LA; Nam JH; Chambers JT; Schwartz PE
Gynecol Oncol; 1990 Mar; 36(3):391-4. PubMed ID: 2318450
[TBL] [Abstract][Full Text] [Related]
3. Urinary gonadotropin fragments (UGF) in cancers of the female reproductive system. II. Initial serial studies.
Wang YX; Schwartz PE; Chambers JT; Cole LA
Gynecol Oncol; 1988 Sep; 31(1):91-102. PubMed ID: 3410359
[TBL] [Abstract][Full Text] [Related]
4. Urinary gonadotropin fragment, a new tumor marker. III. Use in cervical and vulvar cancers.
Nam JH; Chang KC; Chambers JT; Schwartz PE; Cole LA
Gynecol Oncol; 1990 Jul; 38(1):66-70. PubMed ID: 2354828
[TBL] [Abstract][Full Text] [Related]
5. Urinary gonadotropin fragment, a new tumor marker. I. Assay development and cancer specificity.
Nam JH; Cole LA; Chambers JT; Schwartz PE
Gynecol Oncol; 1990 Mar; 36(3):383-90. PubMed ID: 2318449
[TBL] [Abstract][Full Text] [Related]
6. Urinary human chorionic gonadotropin free beta-subunit and beta-core fragment: a new marker of gynecological cancers.
Cole LA; Wang YX; Elliott M; Latif M; Chambers JT; Chambers SK; Schwartz PE
Cancer Res; 1988 Mar; 48(5):1356-60. PubMed ID: 3342414
[TBL] [Abstract][Full Text] [Related]
7. Urinary gonadotropin fragments (UGF) in cancers of the female reproductive system. I. Sensitivity and specificity, comparison with other markers.
Cole LA; Schwartz PE; Wang YX
Gynecol Oncol; 1988 Sep; 31(1):82-90. PubMed ID: 3044936
[TBL] [Abstract][Full Text] [Related]
8. Urinary gonadotropin fragment, a new tumor marker. IV. Use in endometrial cancers and uterine mixed mullerian tumors.
Nam JH; Chambers JT; Schwartz PE; Cole LA
Gynecol Oncol; 1990 Dec; 39(3):352-7. PubMed ID: 2175287
[TBL] [Abstract][Full Text] [Related]
9. The measurement of urinary beta core fragment in conjunction with serum CA125 does not aid the differentiation of malignant from benign pelvic masses.
Carter PG; Iles RK; Neven P; Davies AP; Shepherd JH; Chard T
Gynecol Oncol; 1993 Dec; 51(3):368-71. PubMed ID: 8112647
[TBL] [Abstract][Full Text] [Related]
10. [Urinary gonadotropin fragment measurement in the monitoring of trophoblastic disease].
Fu CY; Cole LA; Kardana A
Zhonghua Fu Chan Ke Za Zhi; 1994 Aug; 29(8):475-7, 510-1. PubMed ID: 7835119
[TBL] [Abstract][Full Text] [Related]
11. Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report.
Cole LA; Tanaka A; Kim GS; Park SY; Koh MW; Schwartz PE; Chambers JT; Nam JH
Gynecol Oncol; 1996 Feb; 60(2):264-70. PubMed ID: 8631549
[TBL] [Abstract][Full Text] [Related]
12. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.
Badgwell D; Lu Z; Cole L; Fritsche H; Atkinson EN; Somers E; Allard J; Moore RG; Lu KH; Bast RC
Gynecol Oncol; 2007 Sep; 106(3):490-7. PubMed ID: 17532030
[TBL] [Abstract][Full Text] [Related]
13. Urinary chorionic gonadotropin subunits and beta-core in nonpregnant women. A study of benign and malignant gynecologic disorders.
Neven P; Iles RK; Lee CL; Hudson CN; Shepherd JH; Chard T
Cancer; 1993 Jun; 71(12):4124-30. PubMed ID: 7685240
[TBL] [Abstract][Full Text] [Related]
14. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.
Chen X; Zhou H; Chen R; He J; Wang Y; Huang L; Sun L; Duan C; Luo X; Yan H
Clin Chim Acta; 2015 Feb; 440():57-63. PubMed ID: 25447698
[TBL] [Abstract][Full Text] [Related]
15. Urinary gonadotropin fragment measurements in patients with lung and esophageal disease.
D'Agostino RS; Cole LA; Ponn RB; Stern H; Schwartz PE
J Surg Oncol; 1992 Mar; 49(3):147-50. PubMed ID: 1548888
[TBL] [Abstract][Full Text] [Related]
16. [Diagnosis of ovarian tumor by measuring tumor markers].
Fukatsu T; Nakashima N; Takeuchi J
Rinsho Byori; 1992 Feb; 40(2):133-8. PubMed ID: 1583785
[TBL] [Abstract][Full Text] [Related]
17. [The values of urine cysteine protein activity in the diagnosis of ovarian cancer].
Xi MR; Peng ZL; Cao ZY
Zhonghua Fu Chan Ke Za Zhi; 1994 Feb; 29(2):85-7, 123. PubMed ID: 8033632
[TBL] [Abstract][Full Text] [Related]
18. Clinical applications of urinary gonadotropin peptides (UGP) in gynecologic oncology.
Schwartz PE; Cracchiolo BM; Cole LA
Anticancer Res; 1996; 16(4B):2135-9. PubMed ID: 8694533
[TBL] [Abstract][Full Text] [Related]
19. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study.
Schutter EM; Mijatovic V; Kok A; Van Kamp GJ; Verstraeten R; Verheijen RH
Anticancer Res; 1999; 19(6C):5551-7. PubMed ID: 10697615
[TBL] [Abstract][Full Text] [Related]
20. [Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (second report)--clinical significance of GAT and comparison with other tumor markers].
Nozawa S; Udagawa Y; Ito K; Susumu N; Sasaki H; Aoki D
Gan To Kagaku Ryoho; 1993 Feb; 20(2):279-85. PubMed ID: 8434967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
